Table 2.

Annualized event rates and hazard ratios for cardiovascular end points and mortality by age group

End PointAge <65 yr (n=2878)Age ≥65 yr (n=1005)
Annual Event Rate Relative HazardAnnual Event Rate Relative Hazard
Placebo (N1=1460)Cinacalcet (N1=1418)Placebo (N1=475)Cinacalcet (N1=530)
Primary composite CVD11.4
(10.6 to 12.3)11.3
(10.5 to 12.2)0.99
(0.88 to 1.11)28.3
(25.9 to 30.9)22.6
(20.5 to 24.7)0.74
(0.63 to 0.86)
All-cause mortality7.0
(6.4 to 7.7)7.1
(6.5 to 7.8)1.01
(0.88 to 1.16)20.4
(18.4 to 22.5)15.9
(14.3 to 17.7)0.73
(0.62 to 0.86)
Myocardial infarction1.9
(1.6 to 2.3)2.4
(2.0 to 2.8)1.2
(0.92 to 1.57)6.3
(5.0 to 7.8)4.0
(3.1 to 5.0)0.60
(0.43 to 0.85)
Unstable angina0.9
(0.7 to 1.2)0.6
(0.4 to 0.9)0.66
(0.43 to 1.03)1.2
(0.7 to 2.0)1.4
(0.9 to 2.1)1.19
(0.62 to 2.29)
Heart failure2.9
(2.5 to 3.4)2.5
(2.1 to 2.9)0.82
(0.64 to 1.03)6.6
(5.3 to 8.1)4.8
(3.8 to 6.0)0.76
(0.56 to 1.05)
Peripheral vascular disease2.3
(1.9 to 2.7)2.2
(1.8 to 2.7)0.99
(0.76 to 1.28)6.3
(5.0 to 7.8)4.2
(4.2 to 5.3)0.69
(0.49 to 0.96)
  • Data are presented with 95% confidence intervals. CVD, cardiovascular disease.